| INTRODUCTION
Our understanding of the gut microbiome in health and disease has increased significantly in recent years. The use of nonculture-dependent techniques, such as 16s rRNA sequencing and more recently metagenomic analysis, has been key in these advances, allowing sequencing of whole populations of microbiota in a short period of time. The advent of these techniques has allowed researchers to examine the impact of the microbiome on a host of different conditions. As the liver receives the majority of its blood supply directly from the microbiota laden gut, via the portal vein, inherently the host microbiome and the liver become intimately linked. This article will examine in detail the role of the gut microbiota in the pathogenesis and progression of chronic liver disease and tease out how modulation of the gut microbiome might offer novel therapeutic targets.
There is a wealth of data to link conditions such as non-alcoholic fatty liver disease (NAFLD), alcohol-related liver disease (ALD) and primary sclerosing cholangitis (PSC) with an altered and potentially "dysfunctional" gut microbiome. The term gut "dysbiosis" has been coined to encapsulate the perturbations in the structure of the complex commensal communities, which can lead to deficient priming of the host immune system leading to a predisposition to develop immune-mediated diseases. Interestingly, emerging evidence suggests that rather than 1 or 2 dominant organisms being responsible for host health, the composition of the entire microbial community contributes to a balanced immune response. The host has also developed a number of mechanisms to counteract changes in the gut microbial community structure. This has broad implications on the development of future therapies that goes beyond the introduction of a single organism to induce health such as introducing a probiotic agent to the diet. It ultimately means that we must identify mechanisms that reconstitute a healthy complex microbiome after dysbiosis has occurred, a process that could be referred to as "rebiosis," which will be fundamental to treating chronic liver disease especially those conditions which may be directly or indirectly immune mediated. The ultimate therapy may, thus, involve transplanting what might be perceived as a healthy gut microbiome from a non-obese healthy donor to a patient with chronic liver disease, an evolving therapy referred to as faecal microbiota transplantation (FMT).
| BACKGROUND

| The rise in chronic liver disease
Liver disease is the fifth biggest killer in England and Wales (British Liver Trust) and unlike mortality for cancer and ischaemic heart disease, mortality from liver disease continues to rise. In Western countries, alcoholic liver disease (ALD) and NAFLD make up the majority of the case-load. The prevalence of NAFLD varies and the prevalence of non-alcoholic steatohepatitis (NASH) is uncertain as it requires a liver biopsy for confirmation. An American study of 328 volunteers found the prevalence of NAFLD was 46% and NASH, which can progress to fibrosis and cirrhosis, was as high as 12%. 1 In diabetic patients, the prevalence was as high as 74% for NAFLD and 22% for NASH; NAFLD being strongly associated with obesity and "the metabolic syndrome." It is estimated that 10%-15% of those who drink to excess develop cirrhosis. The development of cirrhosis is thought to require alcohol intake of at least 50 g of alcohol per day for men or 30 g for women over a period of at least 5 years. 2 NAFLD and ALD together are a huge public health issue and have a considerable financial impact on health services.
| The gut-liver-immune system axis
The gut contains 100 trillion micro-organisms. These out-number somatic cells in the body by 10-fold. 3 The characterisation of gut flora has been greatly improved by 16S ribosomal RNA sequencing as the majority of gut bacteria are unculturable. The gut microbiota includes not only bacteria but also includes viruses and fungi. There are thousands of different bacteria, but the main phyla represented include Bacteroidetes, Firmicutes and Actinobacteria. 4 Many different factors influence microbiota composition, including diet, age and comorbid conditions. In children, the microbiota vary depending on mode of delivery and whether or not the child was breast-fed.
Oligosaccharides from human breast milk promote Lactobacillus and Bifidobacteria, which are the predominant bacteria found in the intestines of breast-fed babies, but these bacteria decline following the introduction of a solid diet. liver is an important immunological organ and is the first organ to challenge gut-derived bacteria, bacterial pathogen-associated molecular patterns (PAMPs) and ingested food products after they enter the systemic circulation. It is for this reason that 80% of the body's resident macrophages reside in the liver. The liver, thus, forms a firewall clearing circulating invading bacteria. 5 The healthy liver is also a site of active local regulation of immune responses favouring induction of T-cell tolerance by the presence of an unique microenvironment rich in tolerogenic organ-resident cells. 6 Any change, therefore, in the gut microbiome composition will impact on homeostatic functions which may induce perturbations in hepatic function and the development of liver disease. 7 Another US study found the NAFLD prevalence to be 46% and the prevalence of biopsy-proven NASH was as high as 12%. 1 Rates were also found to be higher in diabetics and patients from Hispanic backgrounds. With rising rates of obesity, the issue of NAFLD is becoming more and more pressing, especially as there are currently no effective drug treatments for the condition.
Gut microbiota have been implicated in the development of obesity and the metabolic syndrome. 8 Germ-free mice who were fed a high-fat, high-sugar diet gained less weight than ordinary mice fed the same diet. 9 Germ-free mice were then given gut microbiota from normal mice, resulting in increased body fat. Le Roy et al took this one step further, identifying mice with the metabolic syndrome phenotype and treating germ-free mice with "metabolic syndrome" gut microbiota. They then fed the mice a high-fat diet. These mice were compared with germ-free mice treated with "normal" gut microbiota, 12 Zhu et al examined the role of gut microbiota and endogenous alcohol production in NASH development. Twenty-five per cent of those with fatty livers progressed to fibrosis and eventually cirrhosis, while the remaining 75% had simple steatosis and did not progress.
The aim was to discover which co-factors influenced this progression to NASH. Gut microbiota were examined from 3 groups-healthy children, children with biopsy proven NASH and children who were obese, but who had normal liver biochemistry. 13 Children were cho- Small bowel bacterial overgrowth may contribute to excess endogenous alcohol production and hepatic injury. reduced Bacteroidetes species in colonic biopsies in alcohol-exposed subjects has also been observed. 16 This was accompanied by increased levels of Proteobacteria. The alterations were correlated with a high concentration of serum endotoxin in a subset of patients, suggesting the development of bacterial translocation across a compromised intestinal barrier. Changes in microbial function, rather than abundance, could also account for the increased levels of gut-derived pro-inflammatory factors such as endotoxin.
There may also be bacterial groups that differ taxonomically yet are functionally equivalent, and this may differ from individual to individual. Interestingly, while a subset of both actively drinking and abstinent alcohol users had dysbiotic mucosal-associated microbiota, there was no correlation between the duration of sobriety and the presence of dysbiosis, suggesting that the effects of chronic alcohol consumption are not temporary but rather long-lasting.
Alcoholic hepatitis is the most florid form of alcoholic liver disease and has a 28 day mortality approaching 20%. 17 Metabolites in severe AAH-treated mice were also different, with alterations in bile acid composition. Ursodeoxycholic acid (UDCA), a secondary bile acid, and the primary bile acid chenodeoxycholic acid, CDCA, were noted to be increased in the faecal metabolome of non-AAH-treated mice, when compared with severe AAH-treated mice. Moreover, UDCA protects hepatocytes through its antioxidant properties and CDCA can be converted to UDCA by the action of gut bacteria. 19 CDCA also enhances production of alcohol dehydrogenase 1 (ADH1), enhancing alcohol breakdown (Figure 1 ).
Aside from alterations in the bacterial make-up of the gut, alcohol has also been shown to alter the composition of gut dwelling fungi.
Yang et al assessed the impact of chronic alcohol administration on the murine mycobiota (fungal inhabitants) and noted fungal overgrowth. 20 Beta-glucan, a constituent of fungal cell walls, was found in the systemic circulation of the mice exposed to alcohol. Treatment with Amphotericin B reduced translocation of Beta-glucan and improved ALD. Alcohol-dependent human subjects were noted to have reduced fungal diversity and an overgrowth of Candida species.
| Primary sclerosing cholangitis
Primary sclerosing cholangitis is a chronic condition of unclear aetiology causing inflammation and subsequent stricturing of the bile ducts, leading to recurrent episodes of infection and eventually cirrhosis and liver failure. It is often associated with inflammatory bowel disease (IBD), more commonly ulcerative colitis (UC). When the bacterial composition of stool samples from patients with PSC was compared with healthy controls or patients with IBD, 21 3 genera of bacteria were over-represented in PSC (Enterococcus,
Fusobacterium and Lactobacillus) with overall reduced bacterial diversity. This finding was independent of co-existent IBD and UDCA treatment. These changes were most pronounced in those with cirrhosis and previous liver transplantation, compared with those with stable disease. Another study analysing the mucosaassociated bacteria, as opposed to stool, also found a lower bacterial diversity in patients with PSC with an underrepresentation of an uncultured Clostridiales II. 22 This was corroborated by a further study which noted Veillonella to be enriched in patients with PSC.
Microbial communities were similar in PSC patients with and without IBD. 23 While the gut microbial profile in patients with PSC is distinct from patients with UC without biliary disease and healthy controls, another study assessing microbiota obtained from mucosal samples found an enrichment of Blautia and Barnesiellaceae. 24 Cirrhosis reduces beneficial taxa, for example, Lachnospiraceae, Roseburia, Blautia and Ruminococcaceae, which make the SCFA, butyrate. Reduced butyrate disrupts tight junction integrity, allowing movement of LPS from the gut lumen into the portal circulation, where it acts on hepatic macrophages to cause pro-inflammatory cytokine release. Cirrhotic patients also possess increased numbers of pathogenic bacteria such as Enterobacteriaceae, which in turn produce more LPS, also up-regulating inflammation. Bile salt hydrolases expressed by gut bacteria deconjugate primary bile acids. Other bacteria expressing 7a-dehydroxylase convert these to secondary bile acids. These bacteria are altered in cirrhosis, reducing the conversion of primary to secondary bile acids. Bile acids produced in the gut lumen bind to the FXR, producing FGF19, which enters portal circulation and binds to the FGFR4, down-regulating CYP7A1 expressed on the endoplasmic reticulum within hepatocytes. Down-regulation of the CYP7A1 enzyme reduces the production of primary bile acids by the liver, further contributing to the disrupted microbiota. BSEP, Bile salt exporter protein; CDCA, chenodeoxycholic acid; CA, cholic acid; CYP7A1, cytochrome P450 family 7 subtype A polypeptide 1; FXR, farnesoid X receptor; FGF19, fibroblast growth factor 19; FGFR4, fibroblast growth factor receptor 4; LPS, lipopolysaccharide degradation products to the systemic circulation evading the reticuloendothelial system. The evolution of gut dysbiosis has been causally linked to the pathogenesis of cirrhosis and the progression to end-stage liver disease. 32 Indeed, quantitative metagenomic analyses have demonstrated that 75 245 microbial genes differ in abundance between patients with cirrhosis and healthy controls. 33 There is a growing evidence base that supports a relative decrease in the composition of potentially beneficial autochthonous taxa as well as a relative overgrowth of potentially pathogenic taxa (such as Staphylococcaceae, Enterobacteriaceae, and Enterococcaceae), which has been independently associated with severity of liver disease and the development of endotoxemia and multiple endorgan dysfunction. 31, [34] [35] [36] [37] The pathophysiological mechanisms underpinning this are likely to be complex and have been poorly characterised. It has been postulated that the reduced production of SCFAs, anti-bacterial peptides and changes in bile acid production arising from gut dysbiosis all contribute, in part, to worsening disease severity and intestinal decontamination with non-absorbable antibiotics such as rifaximin which has recently been demonstrated to be an effective treatment for HE, 38, 39 implicates gut dysbiosis in contributing to the development of neurocognitive dysfunction. A reduction in the SCFA-producing Lachnospiraceae might also increase colonic pH, hence increasing ammonia production and absorption, resulting in HE. 35 Salivary dysbiosis has also recently been reported to be present in patients with cirrhosis, with an associated systemic and buccal pro-inflammatory milieu. 40 Salivary dysbiosis was more pronounced in over a third of cirrhotic patients that went on to require liverrelated hospital admissions during the 90-day follow-up period, suggesting that saliva may play a key role in maintaining intestinal barrier integrity and tempering oxidative stress. That said, the contribution of salivary dysbiosis compared to distal gut dysbiosis is likely to be trivial due to the quantum difference in the volume of bacteria between the two sites.
| TH E GUT-LIVER-BRAIN AXIS IN CIRRHOSIS
For well over a century, ammonia has been considered central in the pathogenesis of HE in patients with cirrhosis. The majority of circulating ammonia arises from the intestinal breakdown of ingested amino acids and urea by resident gut bacteria. Increased enterocyte expression of enterocyte phosphate-activated glutaminase 41 further augments net intestinal ammonia production and probably also accounts for why germ-free dogs with a portocaval shunt still develop hyperammonemia and HE. 42 In health, ammonia is detoxified to urea in the liver in peri-portal hepatocytes and excreted via the kidneys, or alternatively converted to glutamine by glutamine synthetase (GS) expressing perivenous hepatocytes. Veillonellaceae. 55 These results suggest that rifaximin does not alter the composition of gut bacteria, rather it alters the metabolites of F I G U R E 2 Movement of bacteria from the gut lumen to the liver in health and in cirrhosis. Figure 2 shows movement of bacteria from the gut lumen to the liver in health and in cirrhosis. In health gut barrier, integrity is maintained by a combination of factors including mucus from goblet cells, secretory IgA, bile acids and tight junctions. This prevents unregulated movement of bacteria and endotoxin from the gut to the liver via the portal vein. In cirrhosis, gut dysbiosis and bacterial overgrowth disrupt the usual mechanisms of protection, resulting in increased pathological bacterial translocation (via trans-and para-cellular routes) and endotoxin uptake. These products reach the liver and mesenteric lymph nodes, activating immune cells and causing pro-inflammatory cytokine release (eg TNF-a and IL-8). Circulating neutrophils degranulate in response to systemic TNF-a and IL-8 released from hepatic macrophages (Kupffer cells) in response to the endotoxin exposure (via TLR4 receptors on the macrophages). These neutrophils release a variety of granules including lactoferrin, myeloperoxidase and ROS into the circulation contributing to a systemic inflammatory response. Neutrophils also avidly phagocytose any circulating bacteria as will tissue macrophages. Abbreviations: interleukin-8 (IL-8), Lipopolysaccharide (LPS), reactive oxygen species (ROS), toll-like receptor 4 (TLR4), tumour necrosis factor alpha (TNF-a).
the resident bacteria. Arachidonic and linoleic acids were increased by rifaximin and are known to have a beneficial effect upon brain function, and cognition was improved by rifaximin in this study.
| Probiotics
A recent meta-analysis assessed the impact of probiotics ("healthy" or beneficial bacteria) on HE. The investigators looked at 9 highquality randomised controlled trials assessing the effects of probiotics. They found that probiotics improved both minimal and overt HE. 56 Not only were probiotics noted to reduce arterial ammonia concentrations, but they also reduced the frequency of hospital admissions, rates of infection and progression of minimal to overt HE. Only trials that had confirmed the presence of minimal HE on psychometric testing were included. There were no significant differences in overall mortality or rates of minor adverse events, but probiotics were associated with reduced frequency of severe adverse events. This meta-analysis only included 9 trials that were considered to be of a high standard based on their Jadad scores, but may have excluded trials that had low scores, but were not subject to bias. The probiotics used in each study also varied widely. The need for large-scale high-quality studies of probiotics in HE is clearly warranted.
A phase I study published in 2014 examined the effect of probiotics in cirrhosis. 57 Thirty cirrhotic patients with minimal HE were randomised to receive Lactobacillus GG (LGG) or placebo for 8 weeks. There was no difference between the active treatment group and placebo group with respect to serious adverse events, but the LGG group did experience more diarrhoea (self-limiting). The
LGG group was noted to have altered microbiome, reduced endotoxemia and TNF-a levels, but there was no change in cognition. Dysbiosis was defined as having a low ratio of beneficial taxa (Lachnospiraceae, Clostridiales XIV, Ruminococcaceae and Veillonellaceae) to other taxa (Enterobacteriaceae and Bacteroidaceae). The
LGG-treated group experienced a reduction in dysbiosis. Interestingly, the investigators were not able to appreciate an increase in stool Lactobacillus levels at the thresholds measured. This was postulated to be due to Lactobacillus promoting the growth of other beneficial bacteria. An alternative mechanism postulated that Lactobacillus used their pili to attach to the intestinal mucosa, displacing pathogenic bacteria and hence preventing them from stimulating the host immune system. Further larger scale studies are needed to judge the effectiveness of probiotic treatment upon patient symptoms, but this study suggests that they are safe for use in patients with cirrhosis. Unfortunately to date, the majority of studies of probiotics have been disappointing. The 2015 meta-analysis reviewed 135 studies, but was only able to draw conclusions from 9 studies that they deemed to be of sufficiently high quality. In principle, probiotics should help reconstitute a healthy complex microbiome after dysbiosis has occurred in the cirrhotic gut; however, owing to the trillions of resident bacteria in the human colon, the number of inoculated bacteria given as a probiotic is likely to be wholly insufficient to displace all of the resident dysbiotic bacteria. Cirrhotic subjects often have small bowel bacterial overgrowth, which increases the number of bacteria present in the gut, and when dosed with probiotics, the "healthy bacteria" are required to compete with virulent resident species. The probiotic bacteria may not reach the colon, due to altered intestinal motility or may be destroyed by gastric acid upon ingestion. Cirrhotic patients are often treated with antibiotics for presumed infection, and these drugs may kill off the fragile probiotic species, resulting in as yet disappointing outcomes for probiotics in liver disease.
| Synbiotics
A synbiotic is a healthy bacteria or probiotic, combined with a prebi- 
| Diet
A recent study assessing the impact of iso-caloric high-fat, highsugar and high-protein diets, as well as an unlimited high-fat intake diet, upon the development of NAFLD in rats, showed that diets high in fat and sugar were detrimental to health. The authors also examined the effects of these diets upon gut microbiota composition. 59 Rats fed a high-fat diet (restricted and unrestricted calorie intake) had higher portal LPS levels than the other dietary groups. | 199 hepatic lipogenesis, potentially leading to NAFLD), and gut microbiota in NAFLD. 60 Deficiency of dietary choline (found in eggs and meat as well as cruciferous vegetables) can lead to reversible hepatic steatosis.
Choline may exert its effect by removing fat from hepatocytes. Gut microbiota metabolise choline to methylamine, which not only reduces effective concentrations of choline, but methylamine is itself toxic and pro-inflammatory. Gammaproteobacteria are thought to prevent steatosis in women on a choline-deficient diet. 60 Excess fructose intake may also correlate with NAFLD. A number of studies have found evidence to suggest that excess fructose intake up-regulates de novo lipogenesis and inhibits beta fatty acid oxidation, leading to hepatic steatosis and initiating inflammation via TLR signalling and release of inflammatory cytokines. 60, 61 Fructose also reduces insulin sensitivity. 62 Previously, it was postulated that protein restriction in cirrhosis could reduce nitrogenous load and hence reduce ammonia production, in turn reducing episodes of HE. A Spanish study published in 2004 showed that protein restriction had no impact upon HE in cirrhotic patients. 63 Twenty cirrhotic patients admitted with HE were randomised to receive a low protein diet or a normal diet for 14 days. Protein synthesis and catabolism were measured using radiolabelled glycine-N
15
. The low protein group exhibited higher protein breakdown, with no major benefit upon HE outcomes. Indeed, most patients with cirrhosis are malnourished and protein restriction will undoubtedly worsen their catabolic state; therefore, protein intake should never be restricted in these patients. They assessed the safety of FMT provided by a rationally selected single donor and examined the impact of FMT upon faecal microbiota composition and urinary metabolome. Subjects were pre-treated for 5 days with broad-spectrum antibiotics and 90 ml of FMT was instilled by retention enema. The impact of FMT upon cognitive function was also assessed and found to have a significant positive impact. 66 Our group will be commencing a feasibility study in early 2018
| Faecal microbiota transplantation
[PROFIT Trial] looking at the administration of FMT to patients with cirrhosis to assess the safety and tolerability of the intervention. The ultimate aim of the PROFIT trial is to assess the impact of FMT upon patients with cirrhosis and whether or not this intervention positively alters the gut microbiota and ultimately improves outcomes in this difficult to manage group. This trial differs from those previously undertaken in that the FMT will be administered by upper GI endoscopy in order to deliver microbiota directly to the small bowel where dysbiosis is believed to be greatest. PROFIT will compare FMT to placebo in a single-blinded fashion with a plan to recruit 32 patients, 24 of whom will receive FMT and 8 placebo.
A consensus report was recently published setting out guidance for the use of FMT in recurrent C. difficile infection, IBD, irritable bowel syndrome and the metabolic syndrome. 67 Recommendations were made for the screening of donors and for the archiving of donor and patient samples for review in the case of transmissible infection. Although FMT in liver disease was not explicitly addressed, the recommendations are applicable to our patients, who are relatively immunosuppressed and thus at increased risk of infection due to altered gut permeability.
| TH E FUTUR E
Our evolving knowledge of the dysbiosis which develops in chronic liver disease may help to develop more targeted manipulation of the gut microbiota. Saiedi et al were able to genetically engineer an E. coli strain to specifically target the pathogenic bacteria Pseudomonas aeruginosa. 68 The E. coli vessel was designed to produce a pyocin (a bacterial killing protein that kills P. aeruginosa and not E. coli) in response to detection of the pathogen via quorum sensing. The E. coli cells then auto-lysed, releasing the pyocin and killing any P. aeruginosa in the vicinity. Better understanding of the unique changes seen in cirrhosis may help develop targeted therapies to remove pathogenic strains and selectively re-populate the gut with favourable species.
| CONCLUSION S
As the liver receives the majority of its blood supply directly from the microbiota laden gut, inherently the host microbiome and the liver are intimately linked. This review has examined in detail the role gut microbiota serve in the pathogenesis and progression of chronic liver disease and explored how modulation of the gut microbiome might offer novel therapeutic targets. There is a wealth of data that now link NAFLD, ALD and PSC with an altered and potentially "dysfunctional" gut microbiome. Advanced liver disease is associated with the development of gut dysbiosis, with an overrepresentation of pathogenic bacteria and small bowel bacterial overgrowth. Altered gut permeability, with resultant translocation of endotoxins and bacteria into the portal (and via shunting into the systemic) circulation, results in immune activation and eventual hepatic injury as well as systemic inflammation. Amelioration of the dysbiosis or "rebiosis" could potentially be achieved by manipulation of microbiota through dietary changes and non-absorbable antibiotics such as rifaximin. In an era of multi-drug resistant bacteria, the need for therapies to alter microbiota, without resorting to broad-spectrum antibiotics, is strong. Direct manipulation of the microbiota without drugs may be achieved via probiotic or synbiotic therapy or eventually whole microbiota transplants in the form of FMT. There is an urgent need for large-scale, high-quality studies in this area to assess the most effective way to achieve rebiosis. FMT has the advantage of repopulating the whole dysbiotic gut milieu, but the optimal route of administration, duration of treatment, and durability of response remain to be determined. 
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